Programme
Day 1 - Sunday 2 October 2022
 
12.00 - 13.00
 
Lunch & registration
 
13.00 - 13.10
 
Workshop introduction
 
  Session 1   Overview of landscape
13.10 - 13.40 Peptide talk   PepTherDia - Overview of the landscape of marketed peptides
Vera D'Aloisio, AmbioPharm, US
 
13.40 - 14.10 Oligo talk   Overview of the oligo landscape & ADME strategy for GalNAc-siRNAs
Jesper K Christensen, Novo Nordisk, Denmark
 
14.10 - 14.20
 
Break
 
  Session 2   Metabolism & modelling
14.20 - 14.50 Peptide talk   Comparison of hepatic and extrahepatic in vitro models for peptide metabolism identification
Ari Tolonen, Admescope, Finland
 
14.50 - 15.20 Oligo talk   Physiologically Based Pharmacokinetic Modelling of Oligonucleotide, Bepirovirsen: Exploration of Pharmacokinetic and Dose Adjustment In Hepatitis B Patients
Farzaneh Salem, GSK, UK
 
15.20 - 15.50
 
Break
 
  Session 3   Analytical challenges
15.50 - 16.20 Peptide talk   Perspectives on the past and future of large peptides bioanalysis: with reference to insulins
Michael Blackburn, Quotient Sciences, UK
 
16.20 - 16.50 Oligo talk   Development of an LC-MS/MS method for GSK3389404, a GalNAc conjugated oligonucleotide and it’s non-conjugated metabolite in pre-clinical and clinical studies – challenges and strategies
Alex Bushby, LabCorp, UK
 
16.50 - 17.30
 
Discussion
 
17.30 - 19.00
 
Hit the bar
 
Day 2 - Monday 3 October 2022
 
08.30 - 08.40
 
Day 1 recap & Day 2 agenda
 
  Session 4   DDI
08.40 - 09.10 Peptide talk   EFPIA peptide DDI survey/white paper update
Constanze Hilgendorf, AZ, Sweden
 
09.10 - 09.40 Oligo talk   Considerations & Recommendations for Therapeutic siRNA Plasma Protein Binding Evaluation & Drug-Drug Interaction Risk Assessment
Jan Snoeys, JNJ, Belgium
 
09.40 - 10.00
 
Break
 
  Session 5   Regulatory interactions
10.00 - 10.30 Peptide/
Oligo talk
  Regulatory perspectives of peptides and oligos
Michelle McDonald-Alexis, Parexel, UK (MHRA 2009-2019)
 
10.30 - 11.30
 
Incoming Qs/hot topics/meeting roundup
 
11.30
 
Delegates depart